Dr. Mokenge P. Malafa, MD

Dr. Malafa practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Malafa's NPI, 1699794636, was assigned on July 19, 2006. Dr. Malafa graduated from University of Wisconsin-Madison in 1986. Dr. Malafa holds Florida license ME91541.

Dr. Malafa's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Malafa's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Malafa is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Malafa to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Malafa practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Malafa's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Malafa is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Malafa's licenses on file in 4 states: Florida, California, Illinois and Ohio.

Dmand AI lists abdominal adhesion surgery, colon removal and gallbladder removal among the conditions Dr. Malafa treats.

CMS data shows 105 Medicare services from Dr. Malafa across 4 procedure codes in 2024, for 88 Medicare patients. Medicare paid $5,797 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 88 Medicare patients who saw Dr. Malafa in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Malafa's median patient age at 72, with 49% women.

In 2024, Dr. Malafa wrote 52 Medicare Part D claims for 22 patients. 83% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $444 in total drug cost. In 2022, CMS named 54 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Malafa for performance year 2024, reported as part of a group. Dr. Malafa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Malafa as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 164 papers to Dr. Malafa, published from 2006 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Pancreatic Neoplasms, Adenocarcinoma and Carcinoma, Pancreatic Ductal. Dr. Malafa has published most often in Cancer Control. Dr. Malafa's most frequent co-authors are Pamela J. Hodul, MD, Domenico Coppola, MD and Sarah Elizabeth Hoffe, MD.

Dmand AI links Dr. Malafa to 1 clinical trial. Conditions studied include Pancreatic Neoplasms and Pancreatic Diseases.

CMS Open Payments shows 52 general payments to Dr. Malafa from 6 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 70% of the total. Medtronic, Inc. paid the most, $13,439.

Dmand AI lists 1 award for Dr. Malafa.

Dr. Malafa graduated from University of Wisconsin-Madison in 1986. Dr. Malafa is a member of ACS.

Dr. Malafa is in network with 7 carriers, including Excellus BlueCross BlueShield, Humana and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.